Related Experiment Videos
[The effect of captopril on the progression of heart insufficiency]
1Kardiologische Ambulanz, Städtisches Krankenhaus München-Schwabing.
Insights
Angiotensin-converting enzyme (ACE) inhibitors are essential for treating heart failure, significantly reducing mortality and disease progression. Their benefits in preventing further cardiac events surpass those of other commonly used secondary prophylaxis medications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure is a major cause of morbidity and mortality.
- Secondary prophylaxis aims to prevent adverse cardiac events and disease progression.
Purpose of the Study:
- To evaluate the role of Angiotensin-converting enzyme (ACE) inhibitors in the basic therapy of cardiac failure.
- To compare the therapeutic efficacy of ACE inhibitors with other medications for secondary prophylaxis.
Main Methods:
- Review of existing studies and literature data on ACE inhibitor use in heart failure.
- Analysis of data on disease progression and mortality in patients treated with ACE inhibitors.
- Comparison of therapeutic gain with other commonly used secondary prophylaxis medications.
Main Results:
- ACE inhibitors demonstrate a marked influence on reducing the progression of cardiac failure.
- These agents significantly decrease mortality associated with pump failure.
- The therapeutic gain from ACE inhibitors in heart failure patients exceeds that of other secondary prophylaxis drugs.
Conclusions:
- ACE inhibitors are a cornerstone of basic therapy for cardiac failure.
- Their established efficacy supports their widespread use for improving patient outcomes and survival.
Abstract:
We conclude from our studies and data from the literature that ACE inhibitors belong to the proper basic therapy of cardiac failure because of their marked influence on progression and death by pump failure. The therapeutic gain per 100 patients treated for one year exceeds that of other medications used commonly for secondary prophylaxis.